San Francisco-based iRhythm’s KP-Rhythm2 study — published in the American Journal of Cardiology — examined the efficiency of Zio XT, Holter monitors and event monitors with the aim of assessing diagnostic yield, outcomes and resource utilization by monitoring modality in individuals without previously documented atrial fibrillation (AFib) or atrial flutter (AFL).
Get the full story at our sister site, Medical Design & Outsourcing.
iRhythm’s Zio XT cardiac monitor. [Image from iRhythm]
iRhythm Technologies (NSDQ:IRTC) announced today that a study demonstrated the superiority of its Zio XT compared to other cardiac monitors.San Francisco-based iRhythm’s KP-Rhythm2 study — published in the American Journal of Cardiology — examined the efficiency of Zio XT, Holter monitors and event monitors with the aim of assessing diagnostic yield, outcomes and resource utilization by monitoring modality in individuals without previously documented atrial fibrillation (AFib) or atrial flutter (AFL).
According to a news release, while earlier studies have proven Zio XT to be better than Holter and event monitors for detecting arrhythmias, the KP-Rhythm2 study (led by Kaiser Permanente and supported by a research grant from iRhythm) is the first to specifically address the Zio XT patch up against a 30-day event monitor yielding similar d…
iRhythm’s Zio XT cardiac monitor [Image from iRhythm]
iRhythm Technologies (NSDQ:IRTC) has big plans for 2022 and its remote external electrocardiogram monitors as the medical device developer gears up for growth.President and CEO Quentin Blackford is looking to hire an international general manager among other roles in the coming months, he told Medical Design & Outsourcing after presenting at this month’s 2022 J.P. Morgan Healthcare Conference, where he laid out his vision for profitably scaling the company.
Asked by MDO whether Blackford is planning a reorganization or restructuring after he discussed the cost-consciousness side of his growth plans, an external spokesperson offered more details from the CEO.
“At a leadership level, we are actively structuring our C-suite in order to create long-term sustainable growth,” Blackford said. “The goal is to enable iRhythm to be a glo…
iRhythm’s Zio cardiac monitoring device [Image courtesy of iRhythm]
Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind.iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it grows to serve tens of millions and then hundreds of millions of patients in the years ahead.
“This means introducing things like automation where it’s possible, reconfiguring processes and streamlining systems and structures across the organization, as well as really rethinking how and where we do the work in this new remote environment that we’re proving can be so successful,” Blackford said today at the J.P. Morgan Healthcare Conference. “Ultimat…
As medtech companies continued to drive innovation throughout the past 12 months, a number of high-level executives led the way.
Some of those companies and those executives opted for major changes over the course of 2021, though, with some high-profile moves from medtech giant to medtech giant.
Here are some of the biggest personnel moves in the medtech space in 2021:
1. Medtronic’s internal shuffle causes movement in every directionAt the end of 2020, Medtronic (NYSE:MDT) confirmed that it would reorganize its corporate structure, creating 20 operating units and expecting annual savings of up to $475 million in connection with the changes.
Amid all the change, a number of personnel moves both in and out of the company came over the course of 2021. Among the changes was the big move of Medtronic’s former President of Pelvic Health and Gastric Therapies Brooke Story, who departed to become the worldwide president of BD’s Integra…
Making medical devices: Everything you need to know
The innovation-fueled evolution of drug eluting stents
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
Getting the inside scoop behind top medtech innovationsAutumn is upon us, and it is once again time to sip a pumpkin spice latte — or a pumpkin beer — and crack open our latest Medical Device Handbook.
Once again, we’ve reached out to experts across the industry to curate dozens of “what is” and “how to” types of articles that cover a breadth of categories: components, drug delivery, manufacturing and machining, materials, product design and development, regulatory, software, sterilization services and tubing.
As the years go by, I’m proud that we’re including more insights from the major medical device companies in each succeeding issue. This time around, we spoke to experts involved in some of the major industry innovations of the past decade:
Now VP of R&D …iRhythm’s Zio XT cardiac monitor. [Image from iRhythm]
iRhythm is changing the game in a heart rhythm monitoring space that has been dominated for years by the Holter Monitor. Here’s how.About 14 years ago, when Mark Day was interviewing at iRhythm, he could see the unmet needs that a project out of Stanford’s Biodesign program addressed.
While that was a start, there was still a way to go for what would become a massive disruptor in electrocardiograph monitoring and AFib detection.
“While the design and idea was very compelling — and even 14 years later we’re doing very much what that idea was and have brought it to life and are changing the standard of care as a result — the reality was that it was a hockey puck that never would have adhered very long to the chest. It was very much a concept,” Day, who is now iRhythm’s EVP of R&D, told Medical Design & O…
DeviceTalks Weekly, powered by MassDevice
Please lift this jam-packed episode of the DeviceTalks Weekly Podcast with your legs, not your back.
We’ll hear inspirational words from the legendary Dean Kamen who is shifting his life’s focus into medtech. Todd Pope takes the CEO seat at a new company built to tackle hospital-acquired-infections and COVID Joe Mullings of the Mullings Group explains why now is the best time to be in the Medtech industry.Chris Newmarker, executive editor of life sciences, delivers a murderers row of #newmarkersnewsmakers with Philips, Medtronic, iRyhthm, Canary Medical and Apollo Endosurgery.
To hear Dean Kamen’s entire interview with Design World’s Paul Heney go here.
Thanks for subscribing!
DeviceTalks by MassDevice · Dean Kamen eyeing 3D organs; Todd Pope talks clean air; Joe Mullings says Medtech’s time is now
(From Ishant Mishra on Unsplash)
While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward.
Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while pivoting to artificial-intelligence-based and remote care.
Companies like Moderna arose from nowhere, climbing from a share price of $19.52 to $104.47 over the course of the year as it established itself as a frontronner in the race to get a COVID-19 vaccine to the public, eventually becoming the second vaccine authorized in the U.S.
MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has hit new heights over the course of 2020, indicating the upward trajectory of the industry. Ove…
Juan-Pablo Mas of APVC details the firm’s investment in EXO.
Action Potential Venture Capital, a corporate investment arm of GSK, sees therapeutic opportunities in ultrasound, according to a partner at the group.
In this week’s DeviceTalks Weekly Podcast, Action Venture partner Juan-Pablo Mas explains why APCV led the recent round in Exo, a maker of the first piezoelectric micromachined ultrasonic transducer (PMUT) portable ultrasound imaging technology.
Mas also updates listeners on the venture fund’s interest in exploring other types of technologies. And he introduces LatinxVc, a non-profit group he co-founded to create opportunities for newcomers to venture capital.
Trust Securities Managing Director Kaila Krum says Medtronic (NYSE:MDT) executives are retooling the company to keep pace with smaller, more focused competitors.
Breaking down the company’s Q1 analyst ca…